Organic compounds -- part of the class 532-570 series – Organic compounds – Four or more ring nitrogens in the bicyclo ring system
Reexamination Certificate
2000-09-28
2004-02-10
Raymond, Richard L. (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Four or more ring nitrogens in the bicyclo ring system
C544S236000
Reexamination Certificate
active
06689883
ABSTRACT:
FIELD
This application relates to small molecule heterocyclic pharmaceuticals, and more particularly, to substituted pyridines and pyridazines having angiogenesis inhibiting activity.
BACKGROUND
Vasculogenesis involves the de novo formation of blood vessels from endothelial cell precursors or angioblasts. The first vascular structures in the embryo are formed by vasculogenesis. Angiogenesis involves the development of capillaries from existing blood vessels, and is the principle mechanism by which organs, such as the brain and the kidney are vascularized. While vasculogenesis is restricted to embryonic development, angiogenesis can occur in the adult, for example during pregnancy, the female cycle, or wound healing.
One major regulator of angiogenesis and vasculogenesis in both embryonic development and some angiogenic-dependent diseases is vascular endothelial growth factor (VEGF; also called vascular permeability factor, VPF). VEGF represents a family of mitogens isoforms resulting from alternative mRNA splicing and which exist in homodimeric forms. The VEGF KDR receptor is highly specific for vascular endothelial cells (for reviews, see: Farrara et al.
Endocr. Rev.
1992, 13, 18; Neufield et al.
FASEB J.
1999, 13, 9).
VEGF expression is induced by hypoxia (Shweiki et al.
Nature
1992, 359, 843), as well as by a variety of cytokines and growth factors, such as interleukin-1, interleukin-6, epidermal growth factor and transforming growth factor-&agr; and -&bgr;.
To date VEGF and the VEGF family members have been reported to bind to one or more of three transmembrane receptor tyrosine kinases (Mustonen et al.
J. Cell Biol.,
1995, 129, 895), VEGF receptor-1 (also known as flt-1 (fms-like tyrosine kinase-1)); VEGFR-2 (also known as kinase insert domain containing receptor (KDR), the murine analogue of KDR being known as fetal liver kinase-1 (flk-1)); and VEGFR-3 (also known as flt-4). KDR and flt-1 have been shown to have different signal transduction properties (Waltenberger et al.
J. Biol. Chem.
1994, 269, 26988); Park et al.
Oncogene
1995, 10, 135). Thus, KDR undergoes strong ligand-dependent tyrosine phosphorylation in intact cells, whereas flt-1 displays a weaker response. Thus, binding to KDR is a critical requirement for induction of the full spectrum of VEGF-mediated biological responses.
In vivo, VEGF plays a central role in vasculogenesis, and induces angiogenesis and permeabilization of blood vessels. Deregulated VEGF expression contributes to the development of a number of diseases that are characterized by abnormal angiogenesis and/or hyperpermeability processes. Regulation of the VEGF-mediated signal transduction cascade will therefore provide a useful mode for control of abnormal angiogenesis and/or hyperpermeability processes.
Angiogenesis is regarded as an absolute prerequisite for growth of tumors beyond about 1-2 mm. Oxygen and nutrients may be supplied to cells in tumors smaller than this limit through diffusion. However, every tumor is dependent on angiogenesis for continued growth after it has reached a certain size. Tumorigenic cells within hypoxic regions of tumors respond by stimulation of VEGF production, which triggers activation of quiescent endothelial cells to stimulate new blood vessel formation. (Shweiki et al.
Proc. Nat'l. Acad. Sci.,
1995, 92, 768). In addition, VEGF production in tumor regions where there is no angiogenesis may proceed through the ras signal transduction pathway (Grugel et al.
J. Biol. Chem.,
1995, 270, 25915; Rak et al.
Cancer Res.
1995, 55, 4575). In situ hybridization studies have demonstrated VEGF mRNA is strongly upregulated in a wide variety of human tumors, including lung (Mattern et al.
Br. J. Cancer
1996, 73, 931), thyroid (Viglietto et al.
Oncogene
1995, 11, 1569), breast (Brown et al.
Human Pathol.
1995, 26, 86), gastrointestional tract (Brown et al.
Cancer Res.
1993, 53, 4727; Suzuki et al.
Cancer Res.
1996, 56, 3004), kidney and bladder (Brown et al.
Am. J. Pathol.
1993, 143I, 1255), ovary (Olson et al.
Cancer Res.
1994, 54, 1255), and cervical (Guidi et al.
J. Nat'l Cancer Inst.
1995, 87, 12137) carcinomas, as well as angiosacroma (Hashimoto et al.
Lab. Invest.
1995, 73, 859) and several intracranial tumors (Plate et al.
Nature
1992, 359, 845; Phillips et al.
Int. J. Oncol.
1993, 2, 913; Berkman et al.
J. Clin. Invest.,
1993, 91, 153). Neutralizing monoclonal antibodies to KDR have been shown to be efficacious in blocking tumor angiogenesis (Kim et al.
Nature
1993, 362, 841; Rockwell et al.
Mol. Cell. Differ.
1995, 3, 315).
Overexpression of VEGF, for example under conditions of extreme hypoxia, can lead to intraocular angiogenesis, resulting in hyperproliferation of blood vessels, leading eventually to blindness. Such a cascade of events has been observed for a number of retinopathies, including diabetic retinopathy, ischemic retinal-vein occlusion, retinopathy of prematurity (Aiello et al.
New Engl. J. Med.
1994, 331, 1480; Peer et al.
Lab. Invest.
1995, 72, 638), and age-related macular degeneration (AMD; see, Lopez et al.
Invest. Opththalmol. Vis. Sci.
1996, 37, 855).
In rheumatoid arthritis (RA), the in-growth of vascular pannus may be mediated by production of angiogenic factors. Levels of immunoreactive VEGF are high in the synovial fluid of RA patients, while VEGF levels were low in the synovial fluid of patients with other forms of arthritis of with degenerative joint disease (Koch et al.
J. Immunol.
1994, 152, 4149). The angiogenesis inhibitor AGM-170 has been shown to prevent neovascularization of the joint in the rat collagen arthritis model (Peacock et al.
J. Exper. Med.
1992, 175, 1135).
Increased VEGF expression has also been shown in psoriatic skin, as well as bullous disorders associated with subepidermal blister formation, such as bullous pemphigoid, erythema multiforme, and dermatitis herpetiformis (Brown et al.
J. Invest. Dermatol.
1995, 104, 744).
Because inhibition of KDR signal transduction leads to inhibition of VEGF-mediated angiogenesis and permeabilization, KDR inhibitors will be useful in treatment of diseases characterized by abnormal angiogenesis and/or hyperpermeability processes, including the above listed diseases.
Examples of phthalazines and other fused pyridazines that are similar in structure to those of the present application are disclosed in the following patents or patent applications: WO 9835958 (Novartis), U.S. Pat. Nos. 5,849,741, 3,753,988, 3,478,028 and JP 03106875. Other literature references to phthalazines are El-Feky, S. A., Bayoumy, B. E., and Abd El-Sami, Z. K., Egypt. J. Chem. (1991), Volume Date 1990, 33(2), 189-197; Duhault, J., Gonnard, P., and Fenard, S., Bull. Soc. Chim. Biol., (1967), 49 (2), 177-190; and Holava, H. M. and Jr, Partyka, R. A., J. Med. Chem., (1969), 12, 555-556. The compounds of the present invention are distinct from those described in each of the above references, and only the Novartis publication describes such compounds as inhibitors of angiogenesis.
As explained above, compounds which inhibit angiogenesis have applicability in treatment of a variety of medical conditions, and are therefore desirable. Such materials are the subject of the present application.
SUMMARY
In its broadest aspect, the present invention relates to the sum of three sets of chemical compounds, or pharmaceutically acceptable salts or prodrugs thereof, with each set overlapping the others in scope. The generalized structural formula for the compounds in each of the three sets of compounds is the same, but it should be noted that the definitions of the several groups comprising the general structure in each set differ somewhat. Thus, the defined sets of chemical compounds differ from each other, but overlap in their scopes.
The first set of compounds have the generalized structural formula
wherein
R
1
and R
2
together form a bridge containing two T
2
moieties and one T
3
moiety, said bridge, taken together with the ring to which it is attached, forming a bicyclic of structure
wherein
each
Boyer Stephen James
Dixon Julie A.
Dumas Jacques P.
Joe Teddy Kite
Kluender Harold C. E.
Bayer Pharmaceuticals Corporation
Raymond Richard L.
LandOfFree
Substituted pyridines and pyridazines with angiogenesis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted pyridines and pyridazines with angiogenesis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted pyridines and pyridazines with angiogenesis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3329791